Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Condylomata Acuminata 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Omiganan × Clear all
NCT02596074 2017-08-03

Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN

Maruho Co., Ltd.

Phase 2 Completed
12 enrolled

Usual Type Vulval Intraepithelial Neoplasia (uVIN)

NCT02849262 2017-03-31

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

Maruho Co., Ltd.

Phase 2 Completed
24 enrolled

Condylomata Acuminata

Data powered by HemOnc (CC BY 4.0) Colophon âš¡